Status:
RECRUITING
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Lead Sponsor:
Deciphera Pharmaceuticals, LLC
Conditions:
Healthy Participants
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study...
Eligibility Criteria
Inclusion
- Body mass index (BMI) from 18 to 32 kilogram per square meter (kg/m\^2).
- Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
- Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.
Exclusion
- History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems and/or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease in the opinion of the Investigator.
- Unwilling or unable to comply with the requirements of the protocol.
- Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Key Trial Info
Start Date :
November 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07158411
Start Date
November 20 2025
End Date
June 1 2026
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Vince Clinical Research
Overland Park, Kansas, United States, 66212